| Oct 17 |
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
|
| Oct 15 |
Biodexa announces successful appeal of Nasdaq delisting
|
| Oct 15 |
Biodexa Announces Successful Appeal of Nasdaq Delisting
|
| Oct 4 |
Biodexa reports updated Phase 1 data from glioblastoma study
|
| Oct 4 |
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
|
| Sep 27 |
Biodexa Pharmaceuticals GAAP EPS of -0.10p
|
| Sep 26 |
Interim results for the six months ended June 30, 2024
|
| Sep 19 |
Biodexa Pharmaceuticals announces ADR ratio change
|
| Sep 19 |
ADR Ratio Change
|
| Sep 16 |
Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant
|
